Organization | University of Delaware

University of Delaware Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Newark DE United States (1833)

Organization Overview

First Clinical Trial

2006

NCT00843453

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

University of Delaware | University of Delaware, DE USA

Active Ingredients

Drugs in Phase 4 Trials (3)

celecoxib (celebrex) (1 trial)

estradiol (progynon depot) (2 trials)

ubiquinone (1 trial)

Drugs in Phase 2 Trials (2)

autologous mesenchymal stem cells (1 trial)

nicotinamide (1 trial)

Drugs in Other Trials (11)

aliskiren (tekturna) (1 trial)

cherry (1 trial)

cyanocobalamin (berocca) (1 trial)

estrogen (1 trial)

furosemide (lasix) (1 trial)

melatonin (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

sodium chloride (2 trials)

varenicline (chantix) (1 trial)

vitamin c (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cognitive Dysfunction (Phase 2)

Hypertension (Phase 4)

Kidney Diseases (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 16
# of Trial APIs: 16